Clinical Trial

A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer. The two main questions it aims to answer are : 1. Does SBRT (Stereotactic Body RadioTherapy) for low and intermediate risk prostate cancer patients will result in less genito-urinary (GU) and gastro-intestinal (GI) toxicities than LDRB (Low-Dose Rate Brachytherapy)? 2. Does prostate cancer patients treated by SBRT have a better quality of life than patients treated by LDRB No randomized trial has yet compared LDRB to SBRT head to head.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-21.
Trial Details
NCT Number NCT06052683
Lead Sponsor CHU de Quebec-Universite Laval
Conditions Prostate Cancer
Enrollment 208 participants
Start Date 2019-09-30
Primary Completion 2028-09-30 (estimated)
Study Completion 2029-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-17